SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of December 31, 2022. This document discloses Alphabet's equity securities holdings in other public companies, detailing the number of shares, value, and voting authority for each position.
Key Financial Metrics and Holdings
The filing does not report Alphabet's own revenue, profit, or cash flow. Instead, it lists the value of Alphabet's investment portfolio in other entities. Key metrics include:
- Total Disclosed Positions: The table lists approximately 50 distinct equity positions across various sectors, primarily biotechnology, technology, and healthcare.
- Investment Values: Values range from approximately $383 (Repligen Corp) to over $138 million (Planet Labs PBC).
- Voting Authority: Alphabet holds "Sole" voting authority for the majority of listed positions, with some shared or none depending on the specific security class.
- Top Holdings by Value (Selected):
- Planet Labs PBC: $138,950,488
- Prime Medicine, Inc.: $246,829,503 (Note: Value column indicates total value, though share count is high; specific valuation logic per row varies).
- UiPath Inc (Class A): $173,650,922
- Verve Therapeutics Inc: $200,630,262
- Dexcom Inc: $141,550,000
Material Changes and Portfolio Composition
As a quarterly snapshot, this filing does not explicitly state material changes versus the prior period (Q3 2022) within the text provided. However, the composition highlights a significant concentration in:
- Biotechnology and Life Sciences: Holdings include 23andMe, Alector, Beam Therapeutics, Decibel Therapeutics, and Verve Therapeutics.
- Technology and Software: Holdings include CrowdStrike, GitLab, Snowflake, UiPath, and New Relic.
- Healthcare Services: Holdings include Oscar Health, Invitae, and Exact Sciences.
The filing indicates Alphabet maintains a diverse portfolio of private-to-public transition companies and established tech firms.
Guidance, Risks, and Contingencies
Management Commentary: This filing contains no management commentary, forward-looking guidance, or strategic outlook regarding Alphabet's own operations.
Risks and Contingencies: The filing includes a standard SEC disclaimer stating that the Commission has not reviewed the information for accuracy or completeness. Investors should not assume the data is accurate or complete without independent verification. There are no specific contingencies or unusual items disclosed in this text.
Investor Verification Checklist
- Verify the total aggregate value of Alphabet's 13F holdings against their consolidated balance sheet to assess the scale of these investments relative to total assets.
- Confirm the "Value" column represents the fair market value at the quarter-end (Dec 31, 2022) and not a historical cost basis.
- Check subsequent filings (Q1 2023) to determine if Alphabet increased, decreased, or exited these specific positions.
- Review the "Voting Authority" column to understand the level of control Alphabet exerts over these investee companies.
- Validate the CUSIP numbers for accuracy, particularly for companies with multiple share classes (e.g., Oscar Health, UiPath).